- Conditions
- Overactive Bladder
- Interventions
- Solabegron modified release tablets, low dose, Solabegron modified release tablets, high dose, Matching Placebo
- Drug
- Lead sponsor
- Velicept Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 1,413 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • Guntersville, Alabama • Saraland, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced May 21, 2026, 7:45 PM EDT